Emergent BioSolutions Inc. (EBS) stock
EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3074% below fair value
$5.50−0.11 (-1.96%)
Close on Nov 18, 2026Market cap $282.00MP/E –Yield –
Emergent BioSolutions free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Emergent BioSolutions's free cash flow for the twelve months ending Sep 30, 2026 was $188.40M, up 13357.1% year over year. For fiscal 2025 it was $156.80M, up 338.0% from the year before. The highest annual figure on record is $395.00M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $156.80M | +338.0% |
| FY2024 | Dec 31, 2024 | $35.80M | – |
| FY2023 | Dec 31, 2023 | -$257.90M | – |
| FY2022 | Dec 31, 2022 | -$149.90M | -256.0% |
| FY2021 | Dec 31, 2021 | $96.10M | -75.7% |
| FY2020 | Dec 31, 2020 | $395.00M | +290.7% |
| FY2019 | Dec 31, 2019 | $101.10M | – |
| FY2018 | Dec 31, 2018 | -$30.30M | -119.8% |
| FY2017 | Dec 31, 2017 | $153.30M | – |
| FY2016 | Dec 31, 2016 | -$21.60M | – |
| FY2015 | Dec 31, 2015 | -$2.30M | -102.8% |
| FY2014 | Dec 31, 2014 | $81.65M | +48.6% |
| FY2013 | Dec 31, 2013 | $54.95M | – |
| FY2012 | Dec 31, 2012 | -$14.20M | – |
| FY2011 | Dec 31, 2011 | -$41.84M | -155.1% |
| FY2010 | Dec 31, 2010 | $75.92M | – |
| FY2009 | Dec 31, 2009 | -$3.42M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $96.80M | – |
| Q2 FY2026 | Jun 30, 2026 | $54.00M | -47.8% |
| Q1 FY2026 | Mar 31, 2026 | -$36.20M | – |
| Q4 FY2025 | Dec 31, 2025 | $73.80M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.70M | -103.9% |
| Q2 FY2025 | Jun 30, 2025 | $103.50M | +141.3% |
| Q1 FY2025 | Mar 31, 2025 | -$14.80M | – |
| Q4 FY2024 | Dec 31, 2024 | -$81.60M | -494.2% |
| Q3 FY2024 | Sep 30, 2024 | $147.90M | +212.0% |
| Q2 FY2024 | Jun 30, 2024 | $42.90M | – |
| Q1 FY2024 | Mar 31, 2024 | -$73.40M | – |
| Q4 FY2023 | Dec 31, 2023 | $20.70M | -70.1% |
| Q3 FY2023 | Sep 30, 2023 | $47.40M | – |
| Q2 FY2023 | Jun 30, 2023 | -$126.90M | – |
| Q1 FY2023 | Mar 31, 2023 | -$199.10M | – |
| Q4 FY2022 | Dec 31, 2022 | $69.20M | -75.5% |
| Q3 FY2022 | Sep 30, 2022 | -$101.90M | – |
| Q2 FY2022 | Jun 30, 2022 | -$47.70M | – |
| Q1 FY2022 | Mar 31, 2022 | -$69.50M | – |
| Q4 FY2021 | Dec 31, 2021 | $282.30M | +35.0% |
| Q3 FY2021 | Sep 30, 2021 | -$38.50M | -164.7% |
| Q2 FY2021 | Jun 30, 2021 | -$96.70M | -204.2% |
| Q1 FY2021 | Mar 31, 2021 | -$51.00M | -251.8% |
| Q4 FY2020 | Dec 31, 2020 | $209.10M | +143.1% |
| Q3 FY2020 | Sep 30, 2020 | $59.50M | – |
| Q2 FY2020 | Jun 30, 2020 | $92.80M | – |
| Q1 FY2020 | Mar 31, 2020 | $33.60M | -59.7% |
| Q4 FY2019 | Dec 31, 2019 | $86.00M | – |
| Q3 FY2019 | Sep 30, 2019 | -$18.40M | -112.4% |
| Q2 FY2019 | Jun 30, 2019 | -$49.90M | -337.6% |
| Q1 FY2019 | Mar 31, 2019 | $83.40M | – |
| Q4 FY2018 | Dec 31, 2018 | -$186.60M | -386.8% |
| Q3 FY2018 | Sep 30, 2018 | $147.90M | +567.3% |
| Q2 FY2018 | Jun 30, 2018 | $21.00M | -53.0% |
| Q1 FY2018 | Mar 31, 2018 | -$12.60M | -159.0% |
| Q4 FY2017 | Dec 31, 2017 | $65.07M | – |
| Q3 FY2017 | Sep 30, 2017 | $22.17M | – |
| Q2 FY2017 | Jun 30, 2017 | $44.70M | – |
| Q1 FY2017 | Mar 31, 2017 | $21.37M | – |
| Q4 FY2016 | Dec 31, 2016 | -$32.61M | – |
See a number that looks wrong?